To print this article, all you need is to be registered or login on Mondaq.com.
In order to encourage the development of innovative
pharmaceutical companies in China, patent term extension (PTE) is
introduced for the first time to the amended Chinese Patent Law
that will take effect from June 1, 2021.
PTE was first introduced from the Hatch-Waxman act of the U.S in
1984, with the aim to make up for the time taken for the clinical
trials and market approval of a drug. At the beginning of 2020, PTE
was mentioned in the Economic and Trade Agreement Between China and
the U.S, and then was added to Article 42 of the new Chinese Patent